Date: Saturday, May 30, 2020
Session Time: 3:15pm-4:00pm
Presentation Time: 3:30pm-4:00pm
*Purpose: The lowering of calcineurin inhibitor exposure is possibly considered as the proper strategy to prevent calcineurin inhibitor induced nephrotoxicity in kidney transplant. This clinical study was designed to compare the efficacy and tolerability of reduced-dose tacrolimus with standard-dose mycophenolate mofetil (MMF) versus standard-dose tacrolimus with reduced-dose MMF.
*Methods: A prospective, multicenter, open-label, randomized and parallel-group clinical trial was conducted at four transplant centers in Korea. A total sample size was 108 and eligible patients were randomly assigned in a 1:1 ratio to either reduced-dose tacrolimus with standard-dose MMF (the study group) or standard-dose tacrolimus with reduced-dose MMF (the control group) for six months in de novo kidney transplant recipients. Graft function, the incidence of efficacy failure and adverse events were compared.
*Results: The mean estimated glomerular filtration rate at six months post-transplantation was 69.83 ± 16.68 mL/min/1.73m2 in the study group and 69.92 ± 17.55 mL/min/1.73m2 in the control group (p > 0.05). The overall incidence of biopsy-proven acute rejection was 3.64% (n = 2) in the study group, compared to 3.77% (n = 2) in the control group (p > 0.05). There was no graft loss, death and loss of follow-up in both groups.
*Conclusions: In conclusion, the results suggest that tacrolimus minimization with standard-dose MMF provide adequate immunosuppression with proper renal function and similar rate of incidence of acute rejection compared with the regimen including standard-dose tacrolimus with reduced-dose MMF.
To cite this abstract in AMA style:Bang J, Oh C. Clinical Study of Standard versus Reduced Dose Tacrolimus Combined with Generic Mycophenolate Mofetil in De Novo Kidney Transplantation [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/clinical-study-of-standard-versus-reduced-dose-tacrolimus-combined-with-generic-mycophenolate-mofetil-in-de-novo-kidney-transplantation/. Accessed February 27, 2021.
« Back to 2020 American Transplant Congress